Alzheimer's disease; taking the edge off with cannabinoids?

  title={Alzheimer's disease; taking the edge off with cannabinoids?},
  author={Veronica A. Campbell and Aoife Gowran},
  journal={British Journal of Pharmacology},
Alzheimer's disease is an age‐related neurodegenerative condition associated with cognitive decline. The pathological hallmarks of the disease are the deposition of β‐amyloid protein and hyperphosphorylation of tau, which evoke neuronal cell death and impair inter‐neuronal communication. The disease is also associated with neuroinflammation, excitotoxicity and oxidative stress. In recent years the proclivity of cannabinoids to exert a neuroprotective influence has received substantial interest… 

The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

There is evidence, from in vivo studies on beta-amyloid-induced neurotoxicity, also for a possible causative role of endocannabinoids in the impairment in memory retention, which is typical of AD, which might open the way to the use of cannabinoid receptor antagonists as therapeutic drugs for the treatment of cognitive deficits in the more advanced phases of this disorder.

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.

This review will present a brief introduction to AD biology and current treatment options before outlining comprehensively CBD biology and pharmacology, followed by in-vitro and in- vivo evidence for the therapeutic potential of CBD.

Neurobiological aspects of Alzheimer's disease

AD is a complex multifactorial disorder and thus a single target or pathogenic pathway is unlikely to be identified, and it is hoped that anti-amyloid strategies will offer a significant step towards a causal therapy.

Cannabinoid receptors and neurodegenerative diseases

The cannabinoids belong to an evolutionary conserved neuro-signaling system and certain endogenous and exogenous components of this system are emerging as clinically promising neuroprotective agents due to their anti-oxidative, anti-excitotoxic, and anti-inflammatory properties.

The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration

The experimental and clinical evidence supporting a potential role for CB‐based therapies in the treatment of certain neurological diseases that feature a neurodegenerative component is discussed.

The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.

The role of endocannabinoid signaling in AD is recapitulate and the probable mechanisms through which modulators of the endOCannabinoid system provide their effects are highlighted, thus highlighting how this target might provide more advantages over other therapeutic targets.

Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease

Curcumin significantly alleviated spatial memory deficits in APP/PS1 mice and promoted cholinergic neuronal function in vivo and in vitro, suggesting that PPARγ might be a potential target of curcumin, acting to alleviate neuroinflammation and improve neurons function in AD.

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

Future research should focus on the evaluation of the effects of manipulations to the endocannabinoid system in established animal models for AD, combined with early-phase studies in humans.



A molecular link between the active component of marijuana and Alzheimer's disease pathology.

It is demonstrated that the active component of marijuana, Delta9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid beta-peptide aggregation, the key pathological marker of Alzheimer's disease.

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

It is shown that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microgoo activation.

The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease

The elimination of beta-amyloid-induced oxidative damage through the inhibition of the NADPH oxidase represents an attractive therapeutic target for the treatment of Alzheimer's disease.

Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.

Inflammatory processes in Alzheimer's disease

Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

Although there is still little evidence that inflammation triggers or promotes Alzheimer disease, increasing evidence from mouse models suggests that certain inflammatory mediators are potent drivers of the disease.

The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells

It is reported that cannabidiol inhibits hyperphosphorylation of tau protein in Aβ-stimulated PC12 neuronal cells, which is one of the most representative hallmarks in AD.

Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide

  • N. Milton
  • Biology, Chemistry
    Neuroscience Letters
  • 2002

The role of tau phosphorylation in the pathogenesis of Alzheimer's disease.

Given the increasing evidence that a disruption in the normal phosphorylation state of tau followed by conformational changes plays a key role in the pathogenic events that occur in Alzheimer's disease and other tauopathies; it is critical to elucidate the regulation of t Tau phosphorylated.